Lipocine to Present at 16th Annual Needham Healthcare Conference
March 28 2017 - 8:00AM
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company,
today announced that Mahesh Patel, President and CEO, and Morgan
Brown, Executive Vice President and CFO, will present a company
overview at the 16th Annual Needham Healthcare Conference on
Tuesday, April 4, 2017 at 9:20 a.m. ET.
A live audio webcast of the presentation will be
available via the "Investor Relations" page of the Lipocine
website, www.lipocine.com. Please log on through Lipocine's
website approximately 10 minutes prior to the scheduled start time.
A replay of the webcast will also be archived on Lipocine's website
for 90 days following the presentation
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company
developing innovative pharmaceutical products for use in men's and
women's health using its proprietary drug delivery technologies.
Lipocine’s clinical development pipeline includes three development
programs LPCN 1021, LPCN 1111 and LPCN 1107. LPCN 1021, a
novel oral prodrug of testosterone containing testosterone
undecanoate, is designed to help restore normal testosterone levels
in hypogonadal men. LPCN 1021, was well tolerated and met the
primary efficacy end-point in Phase 3 testing, which utilized
24-hour pharmacokinetic data for dose adjustments, and is currently
being studied in two additional Phase 3 clinical trials. LPCN
1111, a novel oral prodrug of testosterone, originated with and is
being developed by Lipocine as a next-generation oral testosterone
product with potential for once-daily dosing and is currently in
Phase 2 testing. LPCN 1107, the potentially first oral
hydroxyprogesterone caproate product candidate indicated for the
prevention of recurrent preterm birth, has been granted orphan drug
designation by the FDA. An End of Phase 2 meeting with the FDA has
been completed. For more information, please visit
www.lipocine.com.
Forward-Looking Statements
This release contains “forward looking statements”
that are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 and include statements
that are not historical facts regarding Lipocine’s product
candidates and related clinical trials and the FDA review process
relating to its product candidates, plans related to clinical
trials, the possible outcome and timing of such clinical trials,
the expected timing of clinical trial results or any related FDA
review process, the path to approvability by the FDA of Lipocine’s
development programs, the potential uses and benefits of our
product candidates, and our product development efforts. Investors
are cautioned that all such forward-looking statements involve
risks and uncertainties, including, without limitation, the risks
that the FDA will not approve any of our products, risks related to
our products, expected product benefits not being realized,
clinical and regulatory expectations and plans not being realized,
advance regulatory developments and requirements, risks related to
the FDA approval process, the receipt of regulatory approvals, the
results and timing of clinical trials, patient acceptance of
Lipocine’s products, the manufacturing and commercialization of
Lipocine’s products, and other risks detailed in Lipocine’s filings
with the SEC, including, without limitation, its Form 10-K and
other reports on Forms 8-K and 10-Q, all of which can be obtained
on the SEC website at www.sec.gov. Lipocine assumes no obligation
to update or revise publicly any forward-looking statements
contained in this release, except as required by law.
CONTACT:
Morgan Brown
Executive Vice President & Chief Financial Officer
Phone: (801) 994-7383
mb@lipocine.com
Investors:
Hans Vitzhum
Phone: (646) 597-6979
hans@lifesciadviors.com
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2023 to Apr 2024